Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (81-90 of 508) with videos related to

Pageof 51
Sort By:
Innere Medizin (Heidelberg, Germany)|August 24, 2022
[Rhabdomyolysis due to drug-drug interaction of atorvastatin and cobicistat]E Intert, M Krause, F Hennersdorf, et al.
Clinical Chemistry|March 22, 2017
Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy ControlsDavid P Sonne, Dijana Terzic, Filip K Knop, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2024
Letter: Bif195 for aspirin-induced gastric mucosal damage - More to do in further research. Authors' replyNina Løn, Sara Engel, Anders Damholt, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2024
Editorial: The microbiome and gastric mucosal protection in aspirin users-Authors' replyNina Løn, Sara Engel, Anders Damholt, et al.
Expert Opinion on Pharmacotherapy|August 23, 2021
Treatment of type 2 diabetes in children: what are the specific considerations?Magnus F G Grøndahl, Jesper Johannesen, Kurt Kristensen, et al.
Medical & Biological Engineering & Computing|October 24, 2015
A comprehensive compartmental model of blood glucose regulation for healthy and type 2 diabetic subjectsO Vahidi, K E Kwok, R B Gopaluni, et al.
International Journal of Clinical Practice|July 24, 2009
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonistsK B Hansen, F K Knop, J J Holst, et al.
International Journal of Pharmaceutics|September 20, 2012
A comparison of quality control methods for active coating processesD Brock, J A Zeitler, A Funke, et al.
Current Diabetes Reports|October 29, 2017
Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?Magnus F Grøndahl, Damien J Keating, Tina Vilsbøll, et al.
Current Opinion in Molecular Therapeutics|December 15, 2010
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetesEspen Jimenez-Solem, Mette H Rasmussen, Mikkel Christensen, et al.
Pageof 51

Showing results (81-90 of 508) with videos related to

Sort By:
Pageof 51
Innere Medizin (Heidelberg, Germany)|August 24, 2022
[Rhabdomyolysis due to drug-drug interaction of atorvastatin and cobicistat]E Intert, M Krause, F Hennersdorf, et al.
Clinical Chemistry|March 22, 2017
Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy ControlsDavid P Sonne, Dijana Terzic, Filip K Knop, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2024
Letter: Bif195 for aspirin-induced gastric mucosal damage - More to do in further research. Authors' replyNina Løn, Sara Engel, Anders Damholt, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2024
Editorial: The microbiome and gastric mucosal protection in aspirin users-Authors' replyNina Løn, Sara Engel, Anders Damholt, et al.
Expert Opinion on Pharmacotherapy|August 23, 2021
Treatment of type 2 diabetes in children: what are the specific considerations?Magnus F G Grøndahl, Jesper Johannesen, Kurt Kristensen, et al.
Medical & Biological Engineering & Computing|October 24, 2015
A comprehensive compartmental model of blood glucose regulation for healthy and type 2 diabetic subjectsO Vahidi, K E Kwok, R B Gopaluni, et al.
International Journal of Clinical Practice|July 24, 2009
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonistsK B Hansen, F K Knop, J J Holst, et al.
International Journal of Pharmaceutics|September 20, 2012
A comparison of quality control methods for active coating processesD Brock, J A Zeitler, A Funke, et al.
Current Diabetes Reports|October 29, 2017
Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?Magnus F Grøndahl, Damien J Keating, Tina Vilsbøll, et al.
Current Opinion in Molecular Therapeutics|December 15, 2010
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetesEspen Jimenez-Solem, Mette H Rasmussen, Mikkel Christensen, et al.
Pageof 51